GlobeNewsWire
10 Nov 2025, 21:05 UTC · 46w ago
Verdict
Headline takes no side. We score CATX +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Perspective Therapeutics has progressed [ 212 Pb]VMT-α-NET into Cohort 3 following FDA alignment on clinical and dosimetry results.
More positive than 93% of claims this week
The company has initiated dosing for Cohort 3 of VMT-α-NET, with eight patients treated as of September 30, 2025.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 66% of claims this week
The company has begun treating patients with [ 212 Pb]PSV359, with three patients dosed across two cohorts as of October 31, 2025.
More positive than 53% of claims this week
VMT01 is currently in a dose-finding and expansion study for MC1R-positive melanoma patients.
So whatOngoing study progress is standard for biotech development but maintains the potential for future valuation uplifts.
More positive than 44% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
The company reported business highlights and clinical data that validate its technology and progress in cancer treatment trials.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
+24.8%
Price agrees with the score
$2.77 vs $2.22 close before publication (Nov 10) · not market-adjusted
CATX chart →
